A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Inclusion Criteria:

- Informed consent from the subject or a legally acceptable representative (LAR) and
child assent from the subject obtained before any trial-related
activities.Trial-related activities are any procedures that are carried out as part of
the trial, including activities to determine suitability for the trial

- Male or female, above or equal to 10 years and below or equal to 17 years at the time
of signing informed consent/assent

- Diagnosis of type 2 diabetes mellitus at least 3 months prior to screening

- Treated with the maximum tolerated stable dose of metformin for at least 3 months
prior to screening or have documented complete metformin intolerance

- HbA1c (glycosylated haemoglobin) above or equal to 7.0% and below or equal to 10.5%
(above or equal to 53 mmol/mol and below or equal to 91 mmol/mol) at screening

Exclusion Criteria:

- Maturity onset diabetes of the young (MODY)

- Fasting C-peptide at screening below 0.6 ng/mL

- Impaired liver function defined as alanine aminotransferase (ALT) above or equal to
2.5 times upper normal limit

- Known proliferative retinopathy or maculopathy requiring acute treatment as judged by
the investigator

- Treatment with any medication for the indication of diabetes or obesity other than
stated in the inclusion criteria in a period of 3 months before the day of screening